sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
NCT ID: NCT02767921
Last Updated: 2021-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
2 participants
INTERVENTIONAL
2016-08-02
2021-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To determine the feasibility of, and adverse events associated with, treatment with soluble ephrin type-B receptor 4 (sEphB4)-human serum albumin (HSA) (recombinant EphB4-HSA fusion protein) prior to minimally invasive robotic surgery in patients with either muscle-invasive transitional cell carcinoma of the bladder; clear cell renal cell carcinoma (4 cm or greater); or prostate cancer Gleason (7 or under).
SECONDARY OBJECTIVES:
I. To determine tumor response to neoadjuvant sEphB4 as measured by imaging response and pathologic response.
TERTIARY OBJECTIVES:
I. To evaluate the expression of ephrin type-B receptor 4 (EphB4) and eph-related receptor tyrosine kinase ligand 5 (EphrinB2) in the archival tumor samples and explore potential associations with outcome.
II. To bank specimens for future correlative biomarker studies based on the results of ongoing biomarkers analyses in the phase I of sEphB4-HSA as a single agent.
III. To evaluate changes in deoxyribonucleic acid (DNA) methylation of the surgical specimen after being treated with sEphB4-HSA.
IV. To evaluate the infiltration of immune cells into the tumor due to administering sEphB4-HSA.
V. To evaluate the impact sEphB4-HSA has on vessel density on the tumor tissue. VI. To assess the applicability of using sEphB4-HSA for treating genitourinary cancers.
VII. To assess the applicability of using contrast-enhanced ultrasound imaging for determining pathological complete response (pCR) rate.
OUTLINE:
Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes once weekly for 3 weeks (3 doses) in the absence of disease progression or unacceptable toxicity. Patients who agree may receive the fourth dose after an additional week as determined by the study medical oncologist. Two to four weeks after the last dose of recombinant EphB4-HSA fusion protein, patients undergo robotic-assisted radical cystectomy or robotic-assisted radical or partial nephrectomy.
After completion of study treatment, patients are followed up for 30 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (recombinant EphB4-HSA fusion protein, surgery)
Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes once weekly for 3 weeks (3 doses) in the absence of disease progression or unacceptable toxicity. Patients who agree may receive the fourth dose after an additional week as determined by the study medical oncologist. Two to four weeks after the last dose of recombinant EphB4-HSA fusion protein, patients undergo robotic-assisted radical cystectomy or robotic-assisted radical or partial nephrectomy.
Cytology Specimen Collection Procedure
Correlative studies
Laboratory Biomarker Analysis
Correlative studies
Radical Cystectomy
Undergo robotic-assisted radical cystectomy
Recombinant EphB4-HSA Fusion Protein
Given IV
Therapeutic Conventional Surgery
Undergo robotic-assisted radical or partial nephrectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cytology Specimen Collection Procedure
Correlative studies
Laboratory Biomarker Analysis
Correlative studies
Radical Cystectomy
Undergo robotic-assisted radical cystectomy
Recombinant EphB4-HSA Fusion Protein
Given IV
Therapeutic Conventional Surgery
Undergo robotic-assisted radical or partial nephrectomy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* NOTE: HIPAA authorization may be included in the informed consent or obtained separately
* Eastern Cooperative Oncology Group (ECOG) performance status of =\< 1 within 14 days prior to being registered for protocol therapy
* Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after treatment discontinuation
* Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy
* NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal
* Females must not be breastfeeding
* Cohort A - T2, Transitional cell carcinoma (TCC) muscle invasive bladder cancer, (patients who are cisplatin ineligible, decline neoadjuvant and/or ineligible for neoadjuvant chemotherapy); must have histological proof of T2, muscle-invasive transitional cell carcinoma of the bladder with no evidence of metastatic; patient with any degree of fixation of the pelvic sidewall are not eligible
* Cohort B - Prostate cancer (Gleason 7 or less); must have histological proof of Gleason =\< 7 with no evidence of metastatic disease (patient with any degree of extra-prostatic capsule extension are not eligible
* Cohort C - Renal cell carcinoma (\> pT1b); must have radiologic suspicion or histological proof of clear cell renal cell carcinoma \>= 4 cm with no evidence of metastatic disease; patient with any degree of tumor extension into the renal vein are not eligible; patients must be candidates for contrast-enhanced ultrasound (CEUS) imaging and agree to undergo this additional imaging technique
* Patients must be willing to undergo a biopsy of the cancerous tissue if one was not taken within the previous year, prior to drug initiation if tumor block is not available; biopsy must be done within 14 days of first planned drug dose
* Patients must be willing to undergo a radiologic scan (computed tomography \[CT\] or magnetic resonance imaging \[MRI\], depending on organ involved) after last drug dose and prior to minimally-invasive surgery
* Eligible for:
* Cohort A: Robot-assisted radical cystectomy (RARC) as per the attending urologist
* Cohort B: Robot-assisted radical Nephrectomy (RARN)/robot-assisted partial nephrectomy (RAPN) as per the attending urologist
* Cohort C: RAPN as per the attending urologist
* No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancers for which the patient has been disease-free for at least 5 years
* No treatment with any investigational agent within 30 days prior to being registered for protocol therapy
* No prior systemic chemotherapy for transitional cell carcinoma of the bladder (prior intravesical therapy is allowed); any other prior chemotherapy must have been completed \> 5 years prior to initiation of therapy
* Prior radiation therapy is allowed provided that no radiation therapy was administered to the urinary bladder
* NOTE: No radiation therapy within 28 days prior to being registered for protocol therapy; laboratory values must be obtained within 14 days prior to being registered for protocol therapy
* Total bilirubin \< 2.0 X upper limit of normal (ULN)
* Aspartate aminotransferase (AST) =\< 2.5 X ULN
* Alanine aminotransferase (ALT) =\< 2.5 X ULN
* Serum Creatinine \< 2.5 X ULN
* Absolute neutrophil count (ANC) \> 1.5 X K/mm\^3
* Platelets \> 100 K/mm\^3
* International normalized ratio (INR) =\< 1.2
* There are currently no known concomitant medications that must be discontinued prior to administration of registration on study and for the duration of sEphB4-HSA
* No clinically significant infections as judged by the treating investigator
* No pleural or pericardial effusion of any grade
* No uncontrolled angina, congestive heart failure or myocardial infraction (MI) within 6 months prior to registration on study
* No diagnosed arrhythmias
* No abnormalities on pre-entry electrocardiogram, obtained within 28 days prior to being registered on study
* No history of diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
* No abnormalities no history of diagnosed acquired bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies) of registration on protocol therapy
* No abnormalities no history of ongoing or recent (less than or equal to 3 months of registration on protocol therapy) significant gastrointestinal bleeding
* No ongoing anti-coagulation and/or anti-platelet therapies allowed
* Patients with diagnosed uncontrolled hypertension (\> 150/90 mmHg) are to be excluded
* Patients with hypertension controlled with medications are allowed
* No evidence of gross hematuria
* No evidence of hydronephrosis
* No evidence of a history of a stroke or myocardial infarction within the last 6 months prior to study enrollment
* No evidence of a history of wound healing complications prior to study enrollment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Southern California
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David I Quinn, MD
Role: PRINCIPAL_INVESTIGATOR
University of Southern California
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2015-02236
Identifier Type: REGISTRY
Identifier Source: secondary_id
0S-15-6
Identifier Type: OTHER
Identifier Source: secondary_id
0S-15-6
Identifier Type: -
Identifier Source: org_study_id